Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the second quarter ended June 30, 2008.

Total revenues in the second quarter of 2008 were $2.6 million, compared to $4.8 million in the second quarter of 2007, and included $2.0 million in revenue under Arena's contract manufacturing agreement with Siegfried Ltd and $0.6 million in patent reimbursements from Arena's collaborations with Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. Total revenues in the first half of 2008 were $5.3 million, compared to $9.7 million in the first half of 2007. Arena reported a net loss allocable to common stockholders in the second quarter of 2008 of $65.8 million, or $0.89 per share, and a net loss allocable to common stockholders in the first half of 2008 of $120.8 million, or $1.64 per share. This compares with a net loss allocable to common stockholders in the second quarter of 2007 of $39.1 million, or $0.64 per share, and a net loss allocable to common stockholders in the first half of 2007 of $71.5 million, or $1.18 per share.

"Our commitment to generating a robust lorcaserin NDA, as part of our larger plan for discovering and developing innovative therapies, is capital intensive. However, we believe this helps increase our opportunities for success and improve returns for investors that share our mission to develop the best innovative therapies," stated Jack Lief, Arena's President and Chief Executive Officer. "We are well-positioned to continue to build on our accomplishments and achieve key milestones, including results from our pivotal BLOOM obesity trial, results from our APD125 Phase 2b insomnia trial and the advancement of our pipeline as we explore
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Mass., Jan. 13, 2011 Caliper Life Sciences, Inc. ... for the fourth quarter of 2010 of approximately $36.0 ... million, or 10% organic annual growth.  The Company,s fourth ... previous revenue guidance by approximately $2.5 million for this ...
... 13, 2011 Celsion Corporation (Nasdaq: CLSN ... development and commercialization of innovative oncology drugs, today announced ... agreement with a select group of institutional investors, including ... 5,000 shares of 8% redeemable convertible preferred stock with ...
... long-term reversal of tinnitus, a debilitating hearing impairment affecting ... to 40 percent of military veterans, according to an ... Nature . Researchers Dr. Michael Kilgard ... at Dallas and University-affiliated biotechnology firm MicroTransponder report that ...
Cached Biology Technology:Caliper Life Sciences Announces Preliminary Results for the Fourth Quarter and 2010 2Caliper Life Sciences Announces Preliminary Results for the Fourth Quarter and 2010 3Caliper Life Sciences Announces Preliminary Results for the Fourth Quarter and 2010 4Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 3Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 4Nature article focuses on tinnitus treatment 2Nature article focuses on tinnitus treatment 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... of Americans Favor Use of Biometrics in Employment,Verification ... Rosner,Research and Public Opinion Strategies today released results ... verification as a tool for,stemming illegal immigration., ... border (34,percent) and preventing the hiring of illegal ...
... at the John Innes Centre in Norwich have discovered how ... The discovery, described in the forthcoming edition of Science, also ... out as they burrow. The key is in the ... Professor Liam Dolan. We have identified a growth control mechanism ...
... College Park, MD (February 28, 2008) -- Many ... developed by physicists who imported technologies such as ... and radioisotope tagging and detection techniques into the ... (MRI), computerized tomography (CT) scanning, nuclear medicine, positron ...
Cached Biology News:Poll Shows Strong Doubts About Effectiveness of Federal Employment Verification System 2The top 5 ways medical physics has changed health care 2The top 5 ways medical physics has changed health care 3The top 5 ways medical physics has changed health care 4
... For use with suspension ... RiboCap™ uses vacuum filtration or ... culture media. Compatible with ... available in larger package sizes ...
nuclear cap binding protein subunit 1, 80kDa, mRNA...
... Captivate magnetic separator for ... used in conjunction with the ... C-21476) or other magnetic particles ... 96-well microplates. Cell Biology Cell ...
ANTI DEOXY CORTICO...
Biology Products: